A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Kangstem Biotech
- 14 Aug 2019 Planned End Date changed from 1 Jun 2021 to 1 Apr 2021.
- 14 Aug 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Feb 2020.
- 14 Aug 2019 Status changed from not yet recruiting to active, no longer recruiting.